Related Experiment Video
Updated: Sep 13, 2025
Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
Published on: June 18, 2020
Simvastatin Addition to Standard of Care Improves Long-Term Survival in Patients With Cirrhosis After Variceal Bleed:
Randeep Rana1, Mohammed Tabish, Samagra Agarwal
1Department of Gastroenterology and Human Nutrition Unit, All India Institute of Medical Sciences, New Delhi, India.
Insights
Simvastatin addition to standard care significantly improved survival in patients with cirrhosis after variceal bleeding. It also reduced ascites and spontaneous bacterial peritonitis incidence.
Area of Science:
- Hepatology
- Clinical Pharmacology
Background:
- Limited evidence exists on simvastatin's efficacy and safety in decompensated cirrhosis.
- Variceal bleeding is a serious complication in cirrhosis patients, necessitating effective management strategies.
Purpose of the Study:
- To assess if simvastatin improves long-term survival in cirrhosis patients post-variceal bleeding.
- To evaluate the safety and efficacy of simvastatin as an adjunct to standard care.
Main Methods:
- A single-center, open-label, randomized controlled trial was conducted.
- Patients with cirrhosis (Child-Pugh score 5-12) received either simvastatin (20 mg/day) or no drug alongside standard therapy.
- The primary outcome was all-cause mortality over 24 months.
Main Results:
- Simvastatin use was associated with a significant reduction in all-cause mortality (HR 0.48; P=0.006).
- Incidence of ascites and spontaneous bacterial peritonitis was lower in the simvastatin group.
- No significant difference in serious adverse events was observed between groups.
Conclusions:
- Simvastatin may improve survival in selected cirrhosis patients following variceal bleeding.
- Adjunctive simvastatin therapy can reduce the incidence of ascites and its complications.
Introduction:
There is limited evidence about efficacy and safety of simvastatin in decompensated cirrhosis. We assessed whether addition of simvastatin to standard of care improves long-term survival in patients with cirrhosis after variceal bleeding.
Methods:
This was a single-center open label randomized controlled trial with superiority design. Patients with cirrhosis (Child-Pugh score 5-12) were randomly assigned to receive either simvastatin (20 mg once-daily) (n = 130) or no drug (n = 138) in addition to standard therapy (carvedilol and band ligation) at day 5 of variceal bleeding episode. Primary outcome was all-cause mortality over 24-month follow-up. Secondary outcomes included individual complications of cirrhosis with death before decompensation as a competing event.
Results:
Baseline characteristics were similar in both groups with a mean age of 45.0 ± 11.5 years and alcohol (48%) being the predominant etiology. Most patients were of Child-Pugh A (34%) and B (50%) stage. Twenty-four patients (18%) on simvastatin and 44 (31%) on standard therapy died over follow-up (hazard ratio [HR] for simvastatin: 0.48 [95% confidence interval 0.29-0.81]; P = 0.006) with similar results on intention to treat and on per-protocol analysis (excluding 17 patients who stopped simvastatin). Incidence of ascites (subdistributional HR [sHR]) 0.60 (0.39-0.92) and spontaneous bacterial peritonitis (sHR 0.30 [0.11-0.81]) was lower in the simvastatin arm. All cause decompensation (sHR 0.74 [0.52-1.05]), rebleeding (sHR 0.87 [0.57-1.34]), hepatic encephalopathy (sHR 0.71 [0.42-1.19]), and acute-on-chronic liver failure (sHR 0.65 [0.39-1.10]) were comparable in both arms. No heterogeneity of treatment effect was demonstrated across Child-Turcotte-Pugh class ( P = 0.105) or etiology ( P = 0.39). Incidence of serious adverse events was similar (43% in simvastatin and 52% in standard therapy, absolute risk difference: 9.1% [-2.9% to 21.0%]).
Discussion:
Simvastatin may be associated with improved survival in selected patients with cirrhosis after variceal bleed and reduced incidence of new onset/refractory ascites and its complications (CTRI/2022/07/044263).
Related Concept Videos
01:28Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
01:24Esophageal Varices-I: Introduction
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
01:27Coronary Artery Disease V: Interprofessional Care
01:26Varicose Veins II: Diagnostic Studies and Interprofessional Care